Literature DB >> 28612328

Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb.

Maged M Harraz1, Solomon H Snyder2,3,4.   

Abstract

The weeks/months it takes for traditional antidepressants to act pose an obstacle in the management of depression. Ketamine's prompt and sustained antidepressant effects constitute a major advance. Multiple studies implicate glutamatergic signaling to protein synthesis machinery and synapse formation in ketamine's antidepressant effects. Here we review evidence linking ketamine to glutamate receptor subtypes and protein homeostasis. We describe a signaling cascade wherein nitric oxide drives the formation of a ternary protein complex comprised of glyceraldehyde 3-phosphate dehydrogenase, seven in absentia homolog 1, and Ras homolog enriched in brain downstream of the glutamate N-methyl-D-aspartate receptor. Seven in absentia homolog 1 ubiquitylates and degrades Ras homolog enriched in brain leading to inhibition of mechanistic target of rapamycin. Ketamine inhibits this molecular cascade leading to activation of mechanistic target of rapamycin and, in turn, to antidepressant actions.

Entities:  

Keywords:  GAPDH; Glutamate receptor; Ketamine; Nitric oxide; Rheb; mTOR

Mesh:

Substances:

Year:  2017        PMID: 28612328      PMCID: PMC5509634          DOI: 10.1007/s13311-017-0540-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  39 in total

1.  Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

Authors:  Leea H Muhonen; Jouko Lönnqvist; Kati Juva; Hannu Alho
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

2.  Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning.

Authors:  Jonathan L Brigman; Tara Wright; Giuseppe Talani; Shweta Prasad-Mulcare; Seiichiro Jinde; Gail K Seabold; Poonam Mathur; Margaret I Davis; Roland Bock; Richard M Gustin; Roger J Colbran; Veronica A Alvarez; Kazu Nakazawa; Eric Delpire; David M Lovinger; Andrew Holmes
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

3.  Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.

Authors:  C Kiselycznyk; P Svenningsson; E Delpire; A Holmes
Journal:  Neuroscience       Date:  2011-06-23       Impact factor: 3.590

4.  Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Authors:  Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte
Journal:  Int J Geriatr Psychiatry       Date:  2011-12-16       Impact factor: 3.485

5.  Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus.

Authors:  Lêda S B Garcia; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Luciana M Barbosa; Ana Cristina Andreazza; Laura Stertz; Gabriel R Fries; Elaine Cristina Gavioli; Flavio Kapczinski; João Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-08       Impact factor: 5.067

6.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

7.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

8.  Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice.

Authors:  Jian Xu; Pradeep Kurup; Tyler D Baguley; Ethan Foscue; Jonathan A Ellman; Angus C Nairn; Paul J Lombroso
Journal:  Cell Mol Life Sci       Date:  2015-10-08       Impact factor: 9.261

9.  An open-label, flexible-dose study of memantine in major depressive disorder.

Authors:  James M Ferguson; Richard N Shingleton
Journal:  Clin Neuropharmacol       Date:  2007 May-Jun       Impact factor: 1.592

10.  GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.

Authors:  Oliver H Miller; Lingling Yang; Chih-Chieh Wang; Elizabeth A Hargroder; Yihui Zhang; Eric Delpire; Benjamin J Hall
Journal:  Elife       Date:  2014-10-23       Impact factor: 8.140

View more
  5 in total

1.  Moving Beyond Serendipity to Mechanism-Driven Psychiatric Therapeutics.

Authors:  Andrew A Pieper; Jay M Baraban
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

2.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Authors:  Ruin Moaddel; Michelle Shardell; Mohammed Khadeer; Jacqueline Lovett; Bashkim Kadriu; Sarangan Ravichandran; Patrick J Morris; Peixiong Yuan; Craig J Thomas; Todd D Gould; Luigi Ferrucci; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2018-08-16       Impact factor: 4.530

3.  Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches.

Authors:  Pan-Fen Wang; Alicia Neiner; Thomas R Lane; Kimberley M Zorn; Sean Ekins; Evan D Kharasch
Journal:  Mol Pharm       Date:  2019-01-10       Impact factor: 5.364

4.  Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDA receptor antagonist.

Authors:  Marta Gordillo-Salas; Fuencisla Pilar-Cuéllar; Yves P Auberson; Albert Adell
Journal:  Transl Psychiatry       Date:  2018-04-18       Impact factor: 6.222

Review 5.  Leptin in depression: a potential therapeutic target.

Authors:  Tongtong Ge; Jie Fan; Wei Yang; Ranji Cui; Bingjin Li
Journal:  Cell Death Dis       Date:  2018-10-26       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.